Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kazia Therapeutics ( (KZIA) ) has provided an announcement.
In January 2025, Kazia Therapeutics announced the launch of the ABC-Pax study, a novel clinical trial combining paxalisib with immunotherapy for advanced breast cancer treatment. This study, stemming from research with QIMR Berghofer scientists, is a groundbreaking effort to tackle triple-negative breast cancer by combining paxalisib with KEYTRUDA® and LYNPARZA®. The trial, which began enrollment at Royal Brisbane and Women’s Hospital, aims to explore this combination’s safety and efficacy, potentially transforming treatment for this aggressive cancer type. Additionally, the study incorporates a non-invasive liquid biopsy platform for real-time monitoring of treatment effectiveness, marking a significant advancement in precision medicine.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company’s lead program, paxalisib, is a brain-penetrant inhibitor targeting the PI3K / Akt / mTOR pathway, being developed for treating various forms of brain cancer. Kazia has conducted several clinical trials for paxalisib, has received multiple designations from the FDA, and is also developing EVT801, a VEGFR3 inhibitor licensed from Evotec SE.
YTD Price Performance: -20.69%
Average Trading Volume: 99,959
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.05M
For a thorough assessment of KZIA stock, go to TipRanks’ Stock Analysis page.
